Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748355 · ClinicalTrials.gov registry record · NA
Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT03748355: Completed NA study, sponsored by Mayo Clinic.
NCT03748355 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03748355, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
The Researchers are trying to learn more about how individuals break down and process medications based on their genes. The Researchers want to find out whether subjects will have fewer side effects if they take different medications based on their pharmacogenomics profile.
Primary Outcome
Reduction of potential drug interactions risk measured by the numbers in low, medium and high categories.
Interventions
- GENETIC Pharmacogentic Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-10-14 |
| Est. Completion | 2020-01-02 |
| Phase | NA |
What the finished NCT03748355 record still lists
NCT03748355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Pharmacogentic Analysis is the first listed.
NCT03748355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03748355 about?
NCT03748355 is a clinical study titled "Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects". The Researchers are trying to learn more about how individuals break down and process medications based on their genes. The Researchers want to find out whether subjects will have fewer side effects if they take different medications based on their pharmacogenomics profile.
What is the current status of trial NCT03748355?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2018-10-14. Estimated completion is 2020-01-02.
What interventions are being tested in trial NCT03748355?
The interventions under investigation include: Pharmacogentic Analysis (GENETIC).
Who is sponsoring clinical trial NCT03748355?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03748355's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI